What's Happening?
ImmunityBio, a biotechnology company, has reported a substantial increase in net product revenue for the first quarter of 2026, reaching $44.2 million. This represents a 168% year-over-year increase compared to Q1 2025. The growth is attributed to the strong
sales momentum of ANKTIVA, which has seen a 168% increase in unit sales volume. ANKTIVA is now approved in five regulatory jurisdictions, including its first approval in Asia. The company ended the quarter with $380.9 million in cash and marketable securities, up from $242.8 million at the end of 2025. ImmunityBio is also advancing its clinical programs, including a pivotal trial for BCG-naïve NMIBC and a randomized trial for non-small cell lung cancer.
Why It's Important?
The significant revenue growth highlights ImmunityBio's successful commercialization strategy and the increasing demand for ANKTIVA. This financial performance strengthens the company's position in the biotechnology sector and supports its ongoing research and development efforts. The expansion of ANKTIVA's market access, particularly in Asia, opens new opportunities for revenue growth and global presence. The company's robust cash position enables continued investment in clinical trials and potential expansion into new therapeutic areas, reinforcing its commitment to addressing unmet medical needs.
What's Next?
ImmunityBio plans to continue expanding ANKTIVA's market access and advancing its clinical programs. The company is preparing for a supplemental Biologics License Application (sBLA) submission for its BCG-naïve NMIBC trial in 2026. Additionally, ImmunityBio aims to further develop its cell therapy platforms and explore strategic partnerships to enhance its product pipeline. The company's focus on regulatory submissions and market expansion will be critical in sustaining its growth trajectory.
